Integra LifeSciences Prices $450M Senior Secured Notes

Integra LifeSciences Holdings Corporation announced the pricing of $450 million in aggregate principal amount of 9.500% senior secured notes due 2033. The company intends to use the net proceeds, along with borrowings from a new credit facility, to refinance its existing credit facilities and pay associated fees and expenses. This offering is part of a larger refinancing effort, and the company expects the interest rate on these notes, combined with other debt refinancing elements, to result in an effective interest rate increase near the high end of the previously guided 100-200 basis points range.